Mette Bjerre

Low adiponectin levels and increased risk of type 2 diabetes in patients with myocardial infarction

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Standard

Low adiponectin levels and increased risk of type 2 diabetes in patients with myocardial infarction. / Lindberg, Søren; Jensen, Jan S; Pedersen, Sune H; Galatius, Søren; Frystyk, Jan; Flyvbjerg, Allan; Bjerre, Mette; Mogelvang, Rasmus.

I: Diabetes Care, Bind 37, Nr. 11, 11.2014, s. 3003-8.

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Harvard

Lindberg, S, Jensen, JS, Pedersen, SH, Galatius, S, Frystyk, J, Flyvbjerg, A, Bjerre, M & Mogelvang, R 2014, 'Low adiponectin levels and increased risk of type 2 diabetes in patients with myocardial infarction', Diabetes Care, bind 37, nr. 11, s. 3003-8. https://doi.org/10.2337/dc14-0932

APA

Lindberg, S., Jensen, J. S., Pedersen, S. H., Galatius, S., Frystyk, J., Flyvbjerg, A., Bjerre, M., & Mogelvang, R. (2014). Low adiponectin levels and increased risk of type 2 diabetes in patients with myocardial infarction. Diabetes Care, 37(11), 3003-8. https://doi.org/10.2337/dc14-0932

CBE

Lindberg S, Jensen JS, Pedersen SH, Galatius S, Frystyk J, Flyvbjerg A, Bjerre M, Mogelvang R. 2014. Low adiponectin levels and increased risk of type 2 diabetes in patients with myocardial infarction. Diabetes Care. 37(11):3003-8. https://doi.org/10.2337/dc14-0932

MLA

Vancouver

Lindberg S, Jensen JS, Pedersen SH, Galatius S, Frystyk J, Flyvbjerg A o.a. Low adiponectin levels and increased risk of type 2 diabetes in patients with myocardial infarction. Diabetes Care. 2014 nov;37(11):3003-8. https://doi.org/10.2337/dc14-0932

Author

Lindberg, Søren ; Jensen, Jan S ; Pedersen, Sune H ; Galatius, Søren ; Frystyk, Jan ; Flyvbjerg, Allan ; Bjerre, Mette ; Mogelvang, Rasmus. / Low adiponectin levels and increased risk of type 2 diabetes in patients with myocardial infarction. I: Diabetes Care. 2014 ; Bind 37, Nr. 11. s. 3003-8.

Bibtex

@article{908b52875d0c4ed58de32e2ebfd4750f,
title = "Low adiponectin levels and increased risk of type 2 diabetes in patients with myocardial infarction",
abstract = "OBJECTIVE: Patients with acute myocardial infarction (MI) have increased risk of developing type 2 diabetes mellitus (T2DM). Adiponectin is an insulin-sensitizing hormone produced in adipose tissue, directly suppressing hepatic gluconeogenesis, stimulating fatty acid oxidation and glucose uptake in skeletal muscle and insulin secretion. In healthy humans, low plasma adiponectin levels associate with increased risk of T2DM; however, the relationship between adiponectin and T2DM in patients with MI has never been investigated.RESEARCH DESIGN AND METHODS: We prospectively included 666 patients with ST-segment elevation MI, without diabetes, treated with percutaneous coronary intervention, from September 2006 to December 2008 at a tertiary cardiac center. Blood samples were drawn before intervention, and total plasma adiponectin was measured in all samples. During follow-up (median 5.7 years [interquartile range 5.3-6.1]) 6% (n = 38) developed T2DM. Risk of T2DM was analyzed using a competing risk analysis.RESULTS: Low adiponectin levels were associated with increased risk of T2DM (P < 0.001). Even after adjustment for confounding risk factors (age, sex, hypertension, hypercholesterolemia, current smoking, previous MI, BMI, blood glucose, total cholesterol, HDL, LDL, triglyceride, estimated glomerular filtration rate, C-reactive protein, peak troponin I, and proatrial natriuretic peptide), low adiponectin levels remained an independent predictor of T2DM (hazard ratio [HR] 5.8 [2.3-15.0]; P < 0.001). Importantly, plasma adiponectin added to the predictive value of blood glucose, with the combination of high blood glucose and low plasma adiponectin, vastly increasing the risk of developing T2DM (HR 9.6 [3.7-25.3]; P < 0.001).CONCLUSIONS: Low plasma adiponectin levels are independently associated with increased risk of T2DM in patients with MI and added significantly to the predictive value of blood glucose.",
author = "S{\o}ren Lindberg and Jensen, {Jan S} and Pedersen, {Sune H} and S{\o}ren Galatius and Jan Frystyk and Allan Flyvbjerg and Mette Bjerre and Rasmus Mogelvang",
note = "{\textcopyright} 2014 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.",
year = "2014",
month = nov,
doi = "10.2337/dc14-0932",
language = "English",
volume = "37",
pages = "3003--8",
journal = "Diabetes Care",
issn = "0149-5992",
publisher = "American Diabetes Association",
number = "11",

}

RIS

TY - JOUR

T1 - Low adiponectin levels and increased risk of type 2 diabetes in patients with myocardial infarction

AU - Lindberg, Søren

AU - Jensen, Jan S

AU - Pedersen, Sune H

AU - Galatius, Søren

AU - Frystyk, Jan

AU - Flyvbjerg, Allan

AU - Bjerre, Mette

AU - Mogelvang, Rasmus

N1 - © 2014 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.

PY - 2014/11

Y1 - 2014/11

N2 - OBJECTIVE: Patients with acute myocardial infarction (MI) have increased risk of developing type 2 diabetes mellitus (T2DM). Adiponectin is an insulin-sensitizing hormone produced in adipose tissue, directly suppressing hepatic gluconeogenesis, stimulating fatty acid oxidation and glucose uptake in skeletal muscle and insulin secretion. In healthy humans, low plasma adiponectin levels associate with increased risk of T2DM; however, the relationship between adiponectin and T2DM in patients with MI has never been investigated.RESEARCH DESIGN AND METHODS: We prospectively included 666 patients with ST-segment elevation MI, without diabetes, treated with percutaneous coronary intervention, from September 2006 to December 2008 at a tertiary cardiac center. Blood samples were drawn before intervention, and total plasma adiponectin was measured in all samples. During follow-up (median 5.7 years [interquartile range 5.3-6.1]) 6% (n = 38) developed T2DM. Risk of T2DM was analyzed using a competing risk analysis.RESULTS: Low adiponectin levels were associated with increased risk of T2DM (P < 0.001). Even after adjustment for confounding risk factors (age, sex, hypertension, hypercholesterolemia, current smoking, previous MI, BMI, blood glucose, total cholesterol, HDL, LDL, triglyceride, estimated glomerular filtration rate, C-reactive protein, peak troponin I, and proatrial natriuretic peptide), low adiponectin levels remained an independent predictor of T2DM (hazard ratio [HR] 5.8 [2.3-15.0]; P < 0.001). Importantly, plasma adiponectin added to the predictive value of blood glucose, with the combination of high blood glucose and low plasma adiponectin, vastly increasing the risk of developing T2DM (HR 9.6 [3.7-25.3]; P < 0.001).CONCLUSIONS: Low plasma adiponectin levels are independently associated with increased risk of T2DM in patients with MI and added significantly to the predictive value of blood glucose.

AB - OBJECTIVE: Patients with acute myocardial infarction (MI) have increased risk of developing type 2 diabetes mellitus (T2DM). Adiponectin is an insulin-sensitizing hormone produced in adipose tissue, directly suppressing hepatic gluconeogenesis, stimulating fatty acid oxidation and glucose uptake in skeletal muscle and insulin secretion. In healthy humans, low plasma adiponectin levels associate with increased risk of T2DM; however, the relationship between adiponectin and T2DM in patients with MI has never been investigated.RESEARCH DESIGN AND METHODS: We prospectively included 666 patients with ST-segment elevation MI, without diabetes, treated with percutaneous coronary intervention, from September 2006 to December 2008 at a tertiary cardiac center. Blood samples were drawn before intervention, and total plasma adiponectin was measured in all samples. During follow-up (median 5.7 years [interquartile range 5.3-6.1]) 6% (n = 38) developed T2DM. Risk of T2DM was analyzed using a competing risk analysis.RESULTS: Low adiponectin levels were associated with increased risk of T2DM (P < 0.001). Even after adjustment for confounding risk factors (age, sex, hypertension, hypercholesterolemia, current smoking, previous MI, BMI, blood glucose, total cholesterol, HDL, LDL, triglyceride, estimated glomerular filtration rate, C-reactive protein, peak troponin I, and proatrial natriuretic peptide), low adiponectin levels remained an independent predictor of T2DM (hazard ratio [HR] 5.8 [2.3-15.0]; P < 0.001). Importantly, plasma adiponectin added to the predictive value of blood glucose, with the combination of high blood glucose and low plasma adiponectin, vastly increasing the risk of developing T2DM (HR 9.6 [3.7-25.3]; P < 0.001).CONCLUSIONS: Low plasma adiponectin levels are independently associated with increased risk of T2DM in patients with MI and added significantly to the predictive value of blood glucose.

U2 - 10.2337/dc14-0932

DO - 10.2337/dc14-0932

M3 - Journal article

C2 - 25078899

VL - 37

SP - 3003

EP - 3008

JO - Diabetes Care

JF - Diabetes Care

SN - 0149-5992

IS - 11

ER -